NeuPath Health Inc

NeuPath Health Inc operates with a debt-to-equity ratio of 0.55, indicating a moderate reliance on debt financing. The company's liquidity position is characterized by a current ratio of 1.13, suggesting it has sufficient short-term assets to cover its short-term liabilities, though not with a large buffer. Free cash flow stands at 190,000 CAD, which is a positive sign for operational efficiency and the ability to fund growth initiatives or return value to shareholders. Profitability metrics for NeuPath Health Inc are mixed. The company reported a net loss of 378,000 CAD, and its return on equity (ROE) is negative at -1.74%, indicating that the company is not generating returns for its shareholders. Similarly, the return on assets (ROA) is -0.91%, suggesting that the company is not effectively utilizing its assets to generate profit. These figures are below the industry median for healthcare facilities and services, highlighting a need for operational improvements. Geographically and segment-wise, NeuPath Health Inc's revenue concentration is not disclosed in the available data. However, the company's primary business activity is in the biotechnology segment, which is a high-growth area within the healthcare sector. The lack of detailed segment and geographic breakdown limits the ability to assess diversification risks and opportunities. Looking at the growth trajectory, NeuPath Health Inc has reported a revenue of 17,486,000 CAD. While the company is not currently profitable, the positive free cash flow and the presence of a net loss that is narrowing from previous periods suggest potential for future growth. The company's capital expenditure of -47,000 CAD indicates a reduction in investment in physical assets, which could be a strategic move to preserve cash or a sign of operational scaling back. Risk factors for NeuPath Health Inc include a medium liquidity risk, as indicated by the risk assessment. The company's net cash position is negative after accounting for total debt, which could pose challenges in meeting short-term obligations. The dilution risk is assessed as low, with no significant dilution expected in the near term. However, the company's negative net income and operating income suggest financial instability, which could affect its ability to sustain operations without additional financing. Recent events and filings for NeuPath Health Inc do not show any significant developments that would impact the company's financial position or strategic direction. The company's analyst estimates indicate a mean price target of 0.77 CAD, with a median price target of 0.77 CAD. The mean recommendation from analysts is 2.00, which is a "Buy" rating, suggesting that the market has a cautiously optimistic view of the company's prospects.